Diabetic Dermopathy in Man With Long-Standing Diabetes Mellitus

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.

Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.